Estimating The Fair Value Of Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276)
May 22
Chinese (SSE) Healthcare Sector Analysis
UpdatedMay 30, 2024
DataAggregated Company Financials
Companies468
- 7D-3.2%
- 3M-3.5%
- 1Y-18.7%
- YTD-12.2%
The Healthcare industry is down 3.2% over the last week with Shenzhen Mindray Bio-Medical Electronics the worst performer, down 1.9%. Overall the industry is down 19% in 12 months. Looking forward, earnings are forecast to grow by 23% annually.
Sector Valuation and Performance
Has the Chinese Healthcare Sector valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 30 May 2024 | CN¥5.7t | CN¥2.3t | CN¥167.8b | 30x | 33.9x | 2.5x |
| Sat, 27 Apr 2024 | CN¥5.8t | CN¥2.3t | CN¥170.5b | 30.7x | 33.8x | 2.5x |
| Mon, 25 Mar 2024 | CN¥5.9t | CN¥2.3t | CN¥179.8b | 30.9x | 32.8x | 2.6x |
| Wed, 21 Feb 2024 | CN¥5.7t | CN¥2.3t | CN¥179.8b | 28.4x | 31.8x | 2.5x |
| Fri, 19 Jan 2024 | CN¥6.0t | CN¥2.3t | CN¥176.9b | 31.5x | 33.9x | 2.6x |
| Sun, 17 Dec 2023 | CN¥6.5t | CN¥2.3t | CN¥177.1b | 34.8x | 36.7x | 2.8x |
| Tue, 14 Nov 2023 | CN¥6.6t | CN¥2.3t | CN¥177.2b | 35.2x | 37.4x | 2.9x |
| Thu, 12 Oct 2023 | CN¥6.5t | CN¥2.3t | CN¥185.2b | 32.9x | 35x | 2.8x |
| Sat, 09 Sep 2023 | CN¥6.1t | CN¥2.3t | CN¥186.5b | 31.2x | 32.4x | 2.6x |
| Mon, 07 Aug 2023 | CN¥6.5t | CN¥2.3t | CN¥193.1b | 32.5x | 33.5x | 2.8x |
| Wed, 05 Jul 2023 | CN¥6.6t | CN¥2.3t | CN¥191.9b | 34.2x | 34.6x | 2.9x |
| Fri, 02 Jun 2023 | CN¥6.9t | CN¥2.3t | CN¥191.4b | 35.7x | 35.9x | 3x |
| Sun, 30 Apr 2023 | CN¥7.1t | CN¥2.3t | CN¥209.1b | 37x | 33.8x | 3.1x |
| Tue, 28 Mar 2023 | CN¥7.0t | CN¥2.2t | CN¥234.9b | 36.4x | 29.9x | 3.1x |
| Thu, 23 Feb 2023 | CN¥7.4t | CN¥2.2t | CN¥233.2b | 39x | 31.5x | 3.3x |
| Sat, 21 Jan 2023 | CN¥7.4t | CN¥2.2t | CN¥233.4b | 37.8x | 31.9x | 3.4x |
| Mon, 19 Dec 2022 | CN¥7.1t | CN¥2.2t | CN¥231.9b | 38.2x | 30.5x | 3.2x |
| Wed, 16 Nov 2022 | CN¥7.2t | CN¥2.2t | CN¥231.7b | 39.3x | 30.9x | 3.3x |
| Fri, 14 Oct 2022 | CN¥6.2t | CN¥2.1t | CN¥227.5b | 32.2x | 27.2x | 2.9x |
| Sun, 11 Sep 2022 | CN¥6.5t | CN¥2.1t | CN¥222.2b | 33.3x | 29.3x | 3.1x |
| Tue, 09 Aug 2022 | CN¥6.6t | CN¥2.1t | CN¥227.7b | 33.3x | 29x | 3.2x |
| Thu, 07 Jul 2022 | CN¥7.1t | CN¥2.1t | CN¥224.5b | 34.7x | 31.5x | 3.4x |
| Sat, 04 Jun 2022 | CN¥6.2t | CN¥2.0t | CN¥226.1b | 32.7x | 27.5x | 3x |
| Mon, 02 May 2022 | CN¥6.1t | CN¥2.0t | CN¥207.4b | 30.1x | 29.6x | 3x |
| Wed, 30 Mar 2022 | CN¥7.0t | CN¥2.0t | CN¥214.2b | 36.1x | 32.6x | 3.5x |
| Fri, 25 Feb 2022 | CN¥6.8t | CN¥1.9t | CN¥208.6b | 35.2x | 32.7x | 3.5x |
| Sun, 23 Jan 2022 | CN¥7.2t | CN¥1.9t | CN¥205.7b | 38.2x | 35.2x | 3.7x |
| Tue, 21 Dec 2021 | CN¥7.5t | CN¥1.9t | CN¥204.5b | 38.3x | 36.9x | 3.9x |
| Thu, 18 Nov 2021 | CN¥7.8t | CN¥1.9t | CN¥203.5b | 37.3x | 38.3x | 4.1x |
| Sat, 16 Oct 2021 | CN¥7.6t | CN¥1.9t | CN¥204.0b | 36x | 37.3x | 4x |
| Mon, 13 Sep 2021 | CN¥7.5t | CN¥1.9t | CN¥202.2b | 36.6x | 36.9x | 4x |
| Wed, 11 Aug 2021 | CN¥8.1t | CN¥1.9t | CN¥199.3b | 40x | 40.8x | 4.3x |
| Sun, 06 Jun 2021 | CN¥8.9t | CN¥1.8t | CN¥190.1b | 41x | 46.6x | 4.9x |
Price to Earnings Ratio
46.6x
Current Industry PE
- Investors are relatively neutral on the Chinese Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PE ratio of 33.8x.
- The 3-year average PS ratio of 3.3x is higher than the industry's current PS ratio of 2.5x.
Past Earnings Growth
- The earnings for companies in the Healthcare industry have declined 4.1% per year over the last three years.
- Meanwhile revenues for these companies have grown 8.2% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare sector?
| CN Market | -2.62% | |
| Healthcare | -3.24% | |
| Medical Equipment | -2.61% | |
| Pharma | -2.71% | |
| Healthcare Services | -4.13% | |
| Biotech | -4.20% | |
| Healthtech | -5.39% | |
| Life Sciences | -5.40% | |
Industry PE
- Investors are most optimistic about the Healthtech industry even though it's trading below its 3-year average PE ratio of 327x.
- Analysts are expecting annual earnings growth of 47.1%, which is higher than its past year's earnings decline of 22.7% per year.
- Investors are most pessimistic about the Life Sciences industry, which is trading below its 3-year average of 40.8x.
Forecasted Growth
- Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 47% over the next 5 years.
- This is better than its past earnings decline of 23% per year.
- In contrast, the Pharma industry is expected to see its earnings grow by 19% per year over the next few years.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 999 China Resources Sanjiu Medical & Pharmaceutical | CN¥62.14 | 3.7% +CN¥2.2b | -4.9% | PE20x | |
| 300298 Sinocare | CN¥27.82 | 11.6% +CN¥1.6b | -8.3% | PE50.4x | |
| 300573 Shenyang Xingqi PharmaceuticalLtd | CN¥203.19 | 4.1% +CN¥1.4b | 114.6% | PE138.7x | |
| 603392 Beijing Wantai Biological Pharmacy Enterprise | CN¥66.57 | 1.4% +CN¥1.2b | 0.2% | PE657.2x | |
| 2653 Haisco Pharmaceutical Group | CN¥31.35 | 2.4% +CN¥805.5m | 26.5% | PE96.5x |
